Eli Lilly Says Retatrutide Delivers More Than Double Ozempic’s Weight Loss in Late-Stage Diabetes Trial
Lilly’s retatrutide delivered more than double Ozempic’s weight loss in head-to-head diabetes trial
Eli Lilly tested a new medicine called retatrutide. It made people lose more than twice as much weight as a popular competitor medicine. When a company shows its new medicine works better, people often watch to see if it becomes successful and profitable.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.